Report 2017

About the report

A full online version of The Novozymes Report 2017, featuring interactive graphics, is available at report2017.novozymes.com.

 

Editorial team

 

Editor in chief

Anja Berg Winther, Global Communications 

abw@novozymes.com | tel. +45 3077 0421

Finance
Jens Breitenstein, Finance 
jlb@novozymes.com | tel. +45 3077 1087
Jan Paulsen, Finance
jpau@novozymes.com | tel. +45 3077 3208

Investor Relations
Elsebeth Gylling Kjærsgaard, Investor Relations
elgs@novozymes.com | tel. +45 3077 2510

Sustainability
Ridhima Kapur, Corporate Sustainability 
rk@novozymes.com | tel. +91 9535998054

Project Manager
Line Dahlgaard Pedersen, Global Communications 
ledp@novozymes.com | tel. +45 3077 8384

Text

The editorial team from Novozymes, headed by Global Communications

 

Photography

Lars Just and Thorbjørn Hansen

 

Design & web

BystedFFW

 

Editing & proofreading

Borella projects

 

Reporting and audits

The website contains The Novozymes Report 2017 – which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company's annual report – and the financial statements of the parent company Novozymes A/S. Together, these form the company’s annual report that is filed with the Danish Business Authority.

 

PwC has audited the consolidated financial statements, the parent company financial statements, and the environmental and social data. PwC has also been the sustainability assurance provider, basing its assurance on the AA1000 Assurance Standard (2008).

 

The audit covers financial, environmental and social data. These are marked “Audited by PwC.” See also the statements in the report.

 

PwC has not audited the sections of the report found under the headings The big picture, Our business, Governance and Sustainability. The Sustainability section includes our Communication on Progress with respect to the UN Global Compact principles, our report index based on the Global Reporting Initiative (GRI), as well as detailed sustainability data from our main activities in Argentina, Brazil, Canada, China, Denmark, India, the UK and the US.

 

The report has been prepared in accordance with International Financial Reporting Standards (IFRS), the Danish Financial Statements Act and the additional requirements of Nasdaq Copenhagen A/S for the presentation of financial statements by listed companies. It has also been inspired by the GRI's G4 Sustainability Reporting Guidelines. See Basis of reporting in the report for more details.

 

Forward-looking statements

This annual report contains forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "could," "may," "might" and other words of similar meaning.

Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations, both positively and negatively. The risks and uncertainties may, among other things, include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes’ products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes’ core areas; iii) the ability to protect and enforce the company’s intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company’s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; viii) significant price decreases for inputs and materials that compete with Novozymes’ biological solutions. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.